A5056681464- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Cancer survivorship and care
- Childhood Cancer Survivors' Quality of Life
- Multiple and Secondary Primary Cancers
- Palliative Care and End-of-Life Issues
- Family Support in Illness
- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Acute Lymphoblastic Leukemia research
- Global Cancer Incidence and Screening
- Healthcare Policy and Management
- Colorectal Cancer Screening and Detection
- Genomics and Rare Diseases
- Ethics in Clinical Research
- Medication Adherence and Compliance
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Frailty in Older Adults
- Healthcare cost, quality, practices
- Employment and Welfare Studies
- Cancer Risks and Factors
- Pancreatic and Hepatic Oncology Research
- Patient-Provider Communication in Healthcare
- Retirement, Disability, and Employment
University of Colorado Denver
2025
National Cancer Institute
2015-2024
National Institutes of Health
2013-2023
AID Atlanta
2021
Center for Surveillance, Epidemiology, and Laboratory Services
2021
National Human Genome Research Institute
2018
RTI International
2018
Yale University
2015-2018
University of Michigan
2018
American Cancer Society
2015-2017
Cancer survivors represent a growing population, heterogeneous in their need for medical care, psychosocial support, and practical assistance. To inform survivorship research practice, this manuscript will describe the prevalent population of cancer terms overall numbers prevalence by site time since diagnosis.
Healthy People 2020 (HP2020) includes objectives to increase screening for breast, cervical, and colorectal cancer (1) as recommended by the U.S. Preventive Services Task Force (USPSTF).* Progress toward meeting these is monitored measuring test use against national targets using data from National Health Interview Survey (NHIS) (1). Analysis of 2015 NHIS indicated that remains substantially below HP2020 selected tests. Although increased 2000 2015, no improvements in were observed breast...
Abstract Background: No studies have estimated the population-level burden of morbidity in individuals diagnosed with cancer as children (ages 0–19 years). We updated prevalence estimates childhood survivors 2011 and this population reflected by chronic conditions, neurocognitive dysfunction, compromised health-related quality life, health status (general health, mental functional impairment, limitations, pain, fear/anxiety). Methods: Surveillance, Epidemiology, End Results (SEER) Program...
To estimate the prevalence of financial hardship associated with cancer in United States and identify characteristics survivors hardship.We identified 1,202 adult diagnosed or treated at ≥ 18 years age from 2011 Medical Expenditure Panel Survey Experiences With Cancer questionnaire. Material was measured by ever (1) borrowing money going into debt, (2) filing for bankruptcy, (3) being unable to cover one's share medical care costs, (4) making other sacrifices because cancer, its treatment,...
Financial problems caused by cancer and its treatment can substantially affect survivors their families create barriers to seeking health care.The authors identified diagnosed as adults (n=1556) from the nationally representative 2010 National Health Interview Survey. Using multivariable logistic regression analyses, report sociodemographic, clinical, treatment-related factors associated with perceived cancer-related financial association between forgoing or delaying care because of cost....
To present nationally representative estimates of the impact cancer survivorship on medical expenditures and lost productivity among adults in United States.
The rising medical costs associated with cancer have led to considerable financial hardship for patients and their families in the United States. Using data from LIVESTRONG 2012 survey of 4,719 survivors ages 18–64, we examined proportions who reported going into debt or filing bankruptcy as a result cancer, well amount incurred. Approximately one-third had gone debt, 3 percent filed bankruptcy. Of those 55 incurred obligations $10,000 more. Cancer were younger, lower incomes, public health...
Screening for breast cancer, cervical and colorectal cancer (CRC) reduces mortality from these cancers.*However, screening test receipt has been below national targets with disparities observed in certain populations (1,2).National Health Interview Survey (NHIS) data 2018 were analyzed to estimate percentages of adults up date U.S. Preventive Services Task Force (USPSTF) recommendations.Screening remained Healthy People 2020 (HP2020) targets, although CRC neared the target.Disparities...
Abstract Background With aging of the population and improvements in diagnosis, treatment, supportive care, number cancer survivors United States has increased; updated prevalence estimates are needed. Methods Cancer on January 1, 2022, was estimated using Prevalence Incidence Approach Model, utilizing incidence, survival, mortality. by age decade, sex, time from diagnosis calculated. The percentage projected US sex calculated as ratio sex-specific to population. Results There were an 18.1...
BackgroundDuctal carcinoma in situ (DCIS) has a generally favorable overall prognosis, with systemic recurrence rate of approximately 1%, local after mastectomy and breast-conserving treatment less than 10%. Preliminary studies have suggested that women DCIS may overestimate their risk disease recurrence. Few data exist regarding psychosocial outcomes for DCIS.
Purpose There are no nationally representative data on oncologists’ use of next-generation sequencing (NGS) testing in practice. The purpose this study was to investigate how oncologists the United States NGS tests evaluate patients with cancer and inform treatment recommendations. Methods used from National Survey Precision Medicine Cancer Treatment, which mailed a sample 2017 (N = 1,281; cooperation rate 38%). Weighted percentages were calculated describe test use. Multivariable modeling...
Abstract Background: With rising costs of cancer care, this study aims to estimate the prevalence of, and factors associated with, medical financial hardship intensity sacrifices due in United States. Methods: We identified 963 survivors from 2016 Medical Expenditures Panel Survey - Experiences with Cancer. was measured material (e.g., filed for bankruptcy), psychological worry about paying bills finances), behavioral delaying or forgoing care cost) domains. Nonmedical included changes...
Today, there are more than 16.9 million cancer survivors in the United States; this number is projected to grow 22.2 by 2030. Although much progress has been made describing survivors' needs and improving survivorship care since seminal 2006 Institute of Medicine report "From Cancer Patient Survivor: Lost Transition," a need identify evidence gaps research priorities pertaining survivorship. Thus, April 2019, National convened grant-funded extramural researchers, representatives professional...
In the United States in 2019, an estimated 16.9 million persons are living after receiving a cancer diagnosis (1). These survivors face many challenges, including functional limitations, serious psychological distress (2), and other lasting late effects of treatments. Because high cost therapy, more likely to substantial out-of-pocket health care expenditures financial hardship, compared with without history (3,4). Out-of-pocket hardship associated have been higher among aged 18-64 years...
Cancer survivors may experience long-term and late effects from treatment that adversely affect health limit functioning. Few studies examine lost productivity disease burden in cancer compared with individuals who have other chronic conditions or by type.We identified 4960 64,431 the 2008-2010 Medical Expenditure Panel Survey multiple measures of burden, including status productivity, between site for survivors. All analyses controlled age, sex, race/ethnicity, number comorbid...
BACKGROUND Serious psychological distress (SPD) is associated with adverse health outcomes such as poor quality of life and shorter survival in cancer survivors, but to the authors' knowledge, relationship between SPD care use medical expenditures not clear. METHODS A total 4326 survivors 57,109 noncancer participants were identified from 2008 through 2010 Medical Expenditure Panel Survey, a nationwide population‐based survey, their was assessed 6‐item Kessler Psychological Distress Scale...
Cancer centers have a responsibility to help patients manage the costs of their cancer treatment. This article describes availability financial navigation services within National Institute (NCI)-designated centers.Data were obtained from NCI Survey Financial Navigation Services and Research, an online survey administered NCI-designated July September 2019. Of 62 eligible centers, 57 completed all or most survey, for response rate 90.5%.Nearly reported providing with applications...
Abstract Background: It is strongly recommended that adults aged 50–75 years be screened for colorectal cancer. Recommended screening options include colonoscopy, sigmoidoscopy, CT colonography, guaiac fecal occult blood testing (FOBT), immunochemical (FIT), or the more recently introduced FIT-DNA (FIT in combination with a stool DNA test). Colorectal cancer programs can benefit from knowledge of patterns use by test type and within population subgroups. Methods: Using 2018 National Health...
PURPOSE Use of genomic testing, especially multimarker panels, is increasing in the United States. Not all tests and related treatments are covered by health insurance, which can result substantial patient out-of-pocket (OOP) costs. Little known about oncologists' treatment decisions with respect to insurance coverage OOP costs for testing. METHODS We identified 1,049 oncologists who used tumor panels from 2017 National Survey Precision Medicine Cancer Treatment. Separate multivariable...
To meet the complex needs of a growing number cancer survivors, it is essential to accelerate translation survivorship research into evidence-based interventions and, as appropriate, recommendations for care that may be implemented in wide variety settings. Current progress translating stymied, with results many studies un- or underutilized. better understand this problem and identify strategies encourage findings practice, four agencies (American Cancer Society, Centers Disease Control...
The evolution of precision oncology increasingly requires oncologists to incorporate genomic testing into practice. Yet, providers' confidence with is poorly documented. This article describes medical oncologists' and the association between test use.